|
BMC Psychiatry 2012
Methadone treatments in a Swiss Region, 2001–2008: a registry-based analysisKeywords: Opioid substitution, Methadone maintenance, Methadone registry, Treatment duration, Treatment interruption, Switzerland Abstract: A secondary analysis of registry-based data was performed with patients (n?=?2880) registered in the methadone treatment register database of the Public Health Service of the canton of Vaud between January 1, 2001 and June 30, 2008. Survival analysis and multivariate analysis was conducted.The probability of remaining on treatment was 69% at 1 year and 45% at 3 years (n =1666). One-third of patients remained on treatment beyond 5 years. The estimated hazard of leaving treatment was increased by a ratio of 1.31 in the case of a first treatment (P?=?0.001), 1.83 for those without a fixed home (P?<?0.001), and 1.29 for those younger than 30 years old (P?<?0.001). The probability of having begun a new treatment after a first interruption was 21% at one year, 38% at 3 years, and 43% at 5 years (n?=?1581). Factors at the interruption of treatment associated with a higher probability of re-entering were: interruption not due to methadone withdrawal, bad physical health, and higher methadone dose.OSTM are long-term (maintenance) treatments in Switzerland. Younger age, bad living conditions at entry, and first treatment are predictors of lower retention. Approximately one-half of patients who interrupt treatment will re-enter treatment within 5 years.Opioid substitution treatments with methadone (OSTM) have markedly developed in Switzerland (about 7.66 million inhabitants) increasing from approximately 5000 patients on treatment in 1989 to more than 18 000 in 2000 [1]. In 2008, more than 16 500 persons were on OSTM in Switzerland [2], among an estimated number of opiate-dependent persons in Switzerland of 25 000 [3]. The decrease between 2000 and 2008 is estimated to be due to a decrease in the number of new heroin consumers. This evolution has also occurred in other European countries; for example, in Norway, the number of treatments rose from less than 500 in 1998 to 3000 in 2004 [4].First conceived as a therapeutic response that was limited in time and ended with a withdr
|